GLP3-RT

Retatrutide is engineered as a balanced triple agonist, targeting the GLP-1, GIP, and Glucagon receptors in precise ratios to facilitate specialized metabolic studies.

• GLP-1 & GIP Activation: Drives potent appetite suppression signaling, enhances satiety mechanisms, and optimizes glucose pathway research.

• Glucagon Activation: Stimulates metabolic energy expenditure pathways, accelerates lipid oxidation, and targets hepatic fat accumulation.

While glucagon traditionally elevates blood glucose, Retatrutide’s co-activation of GLP-1 and GIP neutralizes glycemic spikes—allowing researchers to investigate the fat-burning and thermogenic benefits of glucagon activation without compromising blood sugar stability.

Disclaimer: This product is sold strictly for research purposes only. Not for human consumption, clinical trials, or therapeutic use.